

## REMARKS

Following entry of the above amendment, claims 1-2, 5, 9-10, 13-15, 17-20, and 23-35 are pending. Claims 3, 4, 6-8, 11, 12, 16, 21, and 22 are canceled without prejudice or disclaimer. Applicants amend claims 5, 9, 13-15, 17-20, and 23-27 to focus on particular embodiments of the invention and to remove multiple dependencies to reduce the filing fee. Applicants add new claims 28-35. No new matter has been added. Support for the new claims is found in the specification as originally filed. See, for example, the claims as originally filed. Applicants amend the specification to add the priority information and correct a spelling error.

Applicants believe the present claims are in condition for allowance and such action is respectfully requested. Applicants believe that no other fees are due in connection with the filing of this paper other than those specifically authorized herewith.

Should any other fees be deemed necessary to effect the timely filing of this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-1701.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: December 31, 2008

/Jennifer Fox, Reg. # 52218/  
Jennifer L Fox, Reg. No. 52,218  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(919) 494-3197